If you have been reading about thymosin beta-4 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
=== Reticular dermis === The reticular dermis is the lower layer of the dermis, found under the papillary dermis, composed of dense irregular connective tissue featuring densely-packed collagen fibers. It is the primary location of dermal elastic fibers. The reticular region is usually much thicker than the overlying papillary dermis. It receives its name from the dense concentration of collagenous, elastic, and reticular fibers that weave throughout it. These protein fibers give the dermis its properties of strength, extensibility, and elasticity. Within the reticular region are the roots of the hair, sebaceous glands, sweat glands, receptors, nails, and blood vessels. The orientation of collagen fibers within the reticular dermis creates lines of tension called Langer's lines, which are of some relevance in surgery and wound healing.
In stress tests performed by Mark Schofield of Fine Woodworking Magazine, "liquid hide glue" compared favourably to normal hide glue in average strength of bond. "However, any liquid hide glue over six months old can be suspect because the urea eventually hydrolyzes the protein structure of the glue and weakens it – even though the product was 'protected' with various bactericides and fungicides during manufacture."
The Ancient Greek word for bone is ὀστέον ("osteon"). In anatomical terminology, including in the Terminologia Anatomica, the word for a bone is os (for example, os breve, os longum, os sesamoideum). (This is not to be confused with the alternative medical use of os to mean orifice, from the Latin ōs, mouth.)
== Synthesis == To begin, this type of collagen is synthesized by the assembly of a specific trimer, when the three NC1 domains initiate molecular interactions between the three α-chains. Protomer trimerization then proceeds from the carboxy terminus to yield the fully assembled protomer. The next step in assembly is collagen IV dimerization. Two collagen IV protomers associate through the carboxy-terminal NC1 trimer to form the NC1 hexamer. These interactions form the core of the type IV collagen scaffold. The scaffold evolves into a collagen IV superstructure by "end-to-end" and lateral connections between collagen IV protomers. The collagen molecule is then formed. Lastly, the type IV collagen molecules bind together to form a complex protein network. To summarize, the process of collagen synthesis occurs mainly in the cells of fibroblasts which are specialized cells with the main function of synthesizing collagen. Collagen synthesis occurs both intracellularly and extracellularly. However, when looking specifically at type IV collagen, it is mostly synthesized extracellularly.
== Bulk properties == Thorium is a moderately soft, paramagnetic, bright silvery radioactive actinide metal that can be bent or shaped. In the periodic table, it lies to the right of actinium, to the left of protactinium, and below cerium. Pure thorium is very ductile and, as normal for metals, can be cold-rolled, swaged, and drawn. At room temperature, thorium metal has a face-centred cubic crystal structure; it has two other forms, one at high temperature (over 1360 °C; body-centred cubic) and one at high pressure (around 100 GPa; body-centred tetragonal). Thorium metal has a bulk modulus (a measure of resistance to compression of a material) of 54 GPa, about the same as tin's (58.2 GPa). Aluminium's is 75.2 GPa; copper's is 137.8 GPa; and mild steel's is 160–169 GPa. Thorium is about as hard as soft steel, so when heated it can be rolled into sheets and pulled into wire. Thorium is nearly half as dense as uranium and plutonium and is harder than both. Thorium has a magnetic susceptibility of 0.412 × 4π × 10−9 m3⋅kg−1 at room temperature. This susceptibility is mostly temperature-independent, however impurities and dopants can affect this value. It becomes superconductive below 1.4 K. Thorium's melting point of 1750 °C is above both those of actinium (1227 °C) and protactinium (1568 °C).
Sources: en.wikipedia.org
== Nixon administration == The war on drugs was declared by President Richard Nixon during a special message to Congress delivered on June 17, 1971, in response to increasing rates of death from narcotics. During his announcement, Nixon mentioned fighting the war on two fronts: the supply front and the demand front. To address the supply front, Nixon requested funding to train narcotics officers internationally and proposed various legislation to disrupt manufacturers of illegal drugs. The demand front referred to enforcement and rehabilitation; Nixon proposed the creation of the Special Action Office of Drug Abuse Prevention to co-ordinate various agencies in addressing demand for illegal drugs. The mission of President Nixon and the United States government was to use the war on drugs to emphasize law enforcement, reduce the supply of illicit drugs, arresting distributors, and attempting to prove a lesson to the people of America to stop using and selling drugs. Although, this drifted towards a focus on minorities. Prisons were filled with individuals arrested for nonviolent drug offenses, and most of the prisoners were a minority in the United States. He also requested an additional $155 million for treatment and rehabilitation programs and additional funding to increase the size and technological capability of the Bureau of Narcotics and Dangerous Drugs.
Evidence indicating that Early to Middle Pleistocene hominins from the northern Indian Subcontinent lived in a mosaic environment dominated by savannas is presented by Kaur et al. (2026). Tu et al. (2026) determine the three crania of Homo erectus from the Yunxian site (Hubei, China) to be approximately 1.77 million years old, representing the oldest securely dated hominin fossils from eastern Asia reported to date. Gousset et al. (2026) study the phylogenetic relationships of Homo luzonensis, and interpret the studied hominin as most likely originating from an Asian population of Homo erectus, resulting in evolutionary reversals in an insular context and likely caused by living in tropical environment. A study on the technological characteristics of the stone tools from the Rizal Archaeological Site (Philippines) is published by Guibert et al. (2026). Li et al. (2026) report a new Lower Paleolithic site with stone tools and animal remains (the Daanmiao site) in the Bailong River valley (Gansu, China) providing evidence of hominin occupation of western Qinling Mountain Ranges approximately 900,000 years ago, and evidence of more favorable habitat for early hominins in the studied area than in other parts of North China during the Mid-Pleistocene Transition. Shao et al. (2026) determine two hominin crania from the Hulu Cave (China) to likely fall within a similar chronological range and date them to Marine Isotope Stage 16. Fu et al.
== Further reading == Khan, Misbah H.; Victor, Frank; Rao, Babar; Sadick, Neil S. (2010). "Treatment of cellulite. Part I. Pathophysiology". Journal of the American Academy of Dermatology. 62 (3): 361–70, quiz 371–2. doi:10.1016/j.jaad.2009.10.042. PMID 20159304. Khan, Misbah H.; Victor, Frank; Rao, Babar; Sadick, Neil S. (2010). "Treatment of cellulite. Part II. Advances and controversies". Journal of the American Academy of Dermatology. 62 (3): 373–84, quiz 385–6. doi:10.1016/j.jaad.2009.10.041. PMID 20159305.
=== Biological antifreezes === Antifreeze proteins refer to chemical compounds produced by certain animals, plants, and other organisms that prevent the formation of ice. In this way, these compounds allow their host organism to operate at temperatures well below the freezing point of water. Antifreeze proteins bind to small ice crystals to inhibit growth and recrystallization of ice that would otherwise be fatal. Cryoprotectants are commonly used in cryobiology to prevent or inhibit freezing in sperm, blood, stem cells, plant seeds, etc. Ethylene glycol, propylene glycol, and glycerol (all used in automotive antifreeze) are commonly used as biological cryoprotectants.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.